A multicenter, open-label, phase II trial of pemetrexed plus bevacizumab in elderly patients with previously untreated advanced or recurrent nonsquamous non-small cell lung cancer.

Yohei YabukiMasaki HanibuchiEiji TakeuchiTakashi HakuTakanori KanematsuNaoki NishimuraYuko ToyodaAtsushi MitsuhashiKenji OtsukaSeidai SatoHisatsugu GotoHiroto YonedaHirokazu OginoHiroshi NokiharaShinohara TsutomuYasuhiko Nishioka

Published in: Thoracic cancer (2023)

Combination chemotherapy with PEM plus Bev in elderly patients with previously untreated advanced non-squamous NSCLC exhibited favorable antitumor activity and tolerability, suggesting that a combination of PEM plus Bev might be a promising treatment option for this population.

Keyphrases

open label
small cell lung cancer
middle aged
advanced non small cell lung cancer
phase ii
clinical trial
phase iii
phase ii study
community dwelling
study protocol
double blind
high grade
placebo controlled
combination therapy
low grade
locally advanced
cross sectional
squamous cell carcinoma
replacement therapy